查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856474

遗传性血管性水肿 (HAE) 治疗市场按治疗类型、药物类别、给药途径、分销管道和最终用户划分 - 全球预测，2025-2032 年

Hereditary Angioedema Therapeutics Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，遗传性血管性水肿 (HAE) 治疗市场将成长至 631.5 亿美元，复合年增长率为 6.45%。

关键市场统计数据
基准年 2024 382.9亿美元
预计年份：2025年 407.7亿美元
预测年份 2032 631.5亿美元
复合年增长率 (%) 6.45%

对重新定义遗传性血管性水肿 (HAE) 的管理和策略重点的临床、商业和监管动态进行简明扼要、综合性的概述

遗传性血管性水肿 (HAE) 是一个独特的治疗领域，其特征是由缓激肽介导的信号通路失调引起的发作性且可能危及生命的水肿。临床治疗已从以急性期住院治疗为主发展为持续性治疗，强调快速按需缓解，并结合预防策略以降低发作频率和严重程度。新型标靶治疗药物、不断改进的给药途径以及不断变化的治疗格局，共同影响临床决策、医疗照护谈判以及病患依从性。

近期治疗创新、剂量调整和新出现的证据如何改变遗传性血管性水肿 (HAE) 的临床路径和商业性价值提案

过去十年，药物治疗模式、照护方式和患者期望都发生了翻天覆地的变化，这些变化正在重塑遗传性血管性水肿 (HAE) 的治疗系统。治疗方法创新已超越传统的血浆替代疗法，发展到生物目标和小分子药物，这些药物旨在抑制激肽释放酶活性或阻断缓激肽信号传导，从而实现按需有效缓解和持续预防。这些进展为临床医生提供了新的选择，但也提高了在真实世界环境中验证疗效、耐受性和依从性的门槛。

近期关税政策调整将如何影响遗传性血管性水肿（HAE）治疗的供应链、生产选择、临床管理和取得途径

贸易政策和关税框架的调整会对依赖复杂生物製药或特殊原料的治疗药物的供应链经济、产品供应和策略采购决策产生重大影响。影响中间体、低温运输运输和医疗设备配件的关税变化会增加製造商的成本结构，并导致不同分销管道的价格差异。相关人员正在预见这些变化，并重新评估其供应商多元化、区域製造地和库存策略，以确保依赖时效性治疗的患者的治疗连续性。

透过分析治疗目的、药理学类别、给药途径、分销管道和最终用户治疗环境，对治疗生态系统进行解构，从而为您的策略提供资讯。

这种治疗领域细分透过明确治疗目的、药理学、给药途径、通路和最终用户环境，商业性和临床决策提供框架。根据治疗类型，重点关注按需介入和预防策略。按需干预包括缓激肽受体拮抗剂、激肽释放酶抑制剂、血浆来源的C1抑制剂和重组C1抑制剂，而预防策略包括单株抗体、口服小分子药物和血浆来源的C1抑制剂。这种治疗类型分类阐明了即时症状控制和长期预防癫痫发作之间的治疗权衡，为临床治疗顺序和个人化治疗方案提供资讯。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 一种基因疗法候选药物有望持久控制遗传性血管性水肿（HAE）发作
  • 扩大基于真实世界证据的研究，以评估预防性治疗方法的长期安全性和有效性
  • 临床试验设计中越来越重视以病人为中心的结果指标和生活品质
  • 整合线上治疗药物分发平台，简化HAE疗法的家庭给药流程
  • 价格压力和不断变化的报销政策影响着新型遗传性血管性水肿（HAE）疗法的可及性
  • 开发具有更长半衰期的新一代单株抗体，用于预防急性HAE发作

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 遗传性血管性水肿 (HAE) 治疗市场（依治疗类型划分）

  • 一经请求
    • 缓激肽受体拮抗剂
    • 激肽释放酶抑制剂
    • 血浆来源的C1抑制剂
    • 重组C1抑制剂
  • 预防
    • 单株抗体
    • 口服小分子
    • 血浆来源的C1抑制剂

9. 依药物类别分類的遗传性血管性水肿 (HAE) 治疗市场

  • 缓激肽受体拮抗剂
  • 激肽释放酶抑制剂
  • 单株抗体
  • 血浆来源的C1抑制剂
  • 重组C1抑制剂

10. 遗传性血管性水肿 (HAE) 治疗市场（依给药途径划分）

  • 静脉注射
  • 口服
  • 皮下

11. 依分销管道分類的遗传性血管性水肿 (HAE) 治疗市场

  • 医院药房
  • 零售药房
  • 专科药房

12. 依最终使用者分類的遗传性血管性水肿 (HAE) 治疗市场

  • 诊所
  • 居家医疗
  • 医院

13. 各地区遗传性血管性水肿 (HAE) 治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 按组别分類的遗传性血管性水肿 (HAE) 治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国遗传性血管性水肿 (HAE) 治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Takeda Pharmaceutical Company Limited
    • CSL Behring AG
    • BioCryst Pharmaceuticals, Inc.
    • Pharming Group NV
    • Ionis Pharmaceuticals, Inc.
Product Code: MRR-742BD517F714

The Hereditary Angioedema Therapeutics Market is projected to grow by USD 63.15 billion at a CAGR of 6.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 38.29 billion
Estimated Year [2025] USD 40.77 billion
Forecast Year [2032] USD 63.15 billion
CAGR (%) 6.45%

A concise integrated overview of clinical, commercial, and regulatory dynamics that are redefining hereditary angioedema management and strategic priorities

Hereditary angioedema remains a distinct therapeutic area characterized by episodic, potentially life-threatening swelling driven by dysregulated bradykinin-mediated pathways. Clinical management has evolved from acute, hospital-centered interventions to a continuum that emphasizes rapid on-demand relief combined with proactive prophylactic strategies to reduce attack frequency and severity. The interplay between novel targeted therapies, evolving administration routes, and shifting care settings now shapes clinical decision-making, payer negotiations, and patient adherence patterns.

This executive summary synthesizes contemporary clinical, commercial, and regulatory dynamics that are reshaping how clinicians, manufacturers, and health systems approach hereditary angioedema. It highlights transformational therapeutic innovations, evaluates the ripple effects of recent trade policy adjustments, and distills segmentation and regional trends that influence go-to-market tactics. The goal is to provide decision-makers with a concise, integrated perspective that supports evidence-driven prioritization of investments, partnerships, and product positioning across both acute and preventive care pathways.

How recent therapeutic innovations, administration shifts, and evidence generation are collectively transforming clinical pathways and commercial value propositions in hereditary angioedema

The past decade has witnessed transformative shifts across drug modalities, care delivery, and patient expectations that are converging to reshape the hereditary angioedema ecosystem. Therapeutic innovation has progressed beyond traditional plasma-derived replacement approaches to include targeted biologics and small molecules designed to interrupt kallikrein activity or block bradykinin signaling, enabling both efficacious on-demand relief and sustained prophylaxis. These advances have introduced new choices for clinicians, but they have also raised the bar for demonstrating comparative effectiveness, tolerability, and real-world adherence.

Concurrently, patient-centric delivery innovations-such as oral prophylactic agents and subcutaneous formulations-have accelerated the movement of care from inpatient settings into clinics and home environments. This decentralization increases the importance of patient education, remote monitoring, and support programs that ensure correct administration and timely escalation of care during breakthrough attacks. Payers and health systems now demand robust value narratives that combine clinical outcomes with evidence of reduced acute care utilization. As a result, manufacturers are investing in longitudinal evidence generation, patient-reported outcomes, and economic modeling to substantiate therapeutic differentiators and to support formulary positioning.

Finally, collaborative pathways between academic centers, specialty pharmacies, and advocacy groups are amplifying real-world data capture and enabling pragmatic comparative analyses. Innovations in registry design, digital symptom tracking, and pharmacovigilance are creating richer evidence streams that inform treatment sequencing and guideline evolution. Taken together, these shifts signal a maturing therapeutic landscape where scientific innovation is tightly linked to delivery model redesign and value demonstration.

Assessing how recent tariff policy adjustments can ripple through supply chains, manufacturing choices, clinical administration, and access pathways for hereditary angioedema treatments

The introduction of adjustment in trade policy and tariff frameworks can materially influence supply chain economics, product availability, and strategic sourcing decisions for therapeutics that rely on complex biologic production or specialized raw materials. Tariff changes affecting intermediate components, cold-chain transport, and medical device accessories elevate cost structures for manufacturers and can introduce variability in pricing across distribution channels. Anticipating such shifts, stakeholders are reevaluating supplier diversification, regional manufacturing footprints, and inventory strategies to preserve continuity of care for patients dependent on time-sensitive therapies.

Manufacturers that source critical inputs internationally may respond by regionalizing production or establishing contingency inventory hubs to mitigate the operational impact of tariff-driven cost pressures. These actions, while stabilizing supply, require capital allocation and lead-time adjustments that influence product launch sequencing and contracting negotiations with payers and providers. For clinically administered treatments, increased logistics complexity can also affect hospital and clinic procurement practices, leading institutions to favor therapies with simpler storage and handling requirements when clinically appropriate.

Moreover, tariffs can indirectly shape competitive dynamics by altering total delivered cost across routes of administration. For example, therapies that reduce dependence on intravenous administration and complex hospital services may present an advantage in environments where tariffs elevate the cost of imported infusion-related components. In parallel, specialty pharmacies and home care providers will need to adapt their procurement and reimbursement strategies to reflect any incremental cost burdens, working with manufacturers and payers to preserve patient access while maintaining sustainable margins. Ultimately, productive engagement between industry, policy stakeholders, and supply chain partners will be essential to navigate tariff-driven disruptions and to safeguard stable access to lifesaving therapeutics.

Deconstructing the therapeutic ecosystem through treatment intent, pharmacologic class, administration routes, distribution channels, and end-user care settings to inform strategy

Segmentation in this therapeutic area frames commercial and clinical decision-making by delineating treatment intent, pharmacology, administration route, distribution pathways, and end-user environments. Based on treatment type, emphasis is placed on both On Demand interventions and Prophylaxis strategies; On Demand interventions include bradykinin receptor antagonists, kallikrein inhibitors, plasma derived C1 inhibitors, and recombinant C1 inhibitors, while Prophylaxis strategies encompass monoclonal antibodies, oral small molecules, and plasma derived C1 inhibitors. This treatment-type taxonomy clarifies the therapeutic trade-offs between immediate symptomatic control and long-term attack prevention, informing clinical sequencing and patient-tailored regimens.

Based on drug class, analyzers consider bradykinin receptor antagonists, kallikrein inhibitors, monoclonal antibodies, plasma derived C1 inhibitors, and recombinant C1 inhibitors as distinct mechanisms with different safety profiles, administration requirements, and evidence expectations. These pharmacologic categorizations drive differential value messages to payers and clinicians, particularly when head-to-head comparative evidence remains limited. Based on route of administration, distinctions among intravenous, oral, and subcutaneous formats materially influence site-of-care economics, patient adherence, and design of support services, since intravenous therapies often require facility-based delivery whereas oral and subcutaneous options facilitate clinic or home administration.

Distribution channel segmentation further shapes commercial execution and access pathways, with hospital pharmacies, retail pharmacies, and specialty pharmacies each playing specific roles in dispensing, reimbursement navigation, and patient support. Hospital pharmacies remain central for acute administration and inpatient management, retail pharmacies provide convenience for routine refills and community access, and specialty pharmacies deliver care coordination and claims expertise for high-cost or complex therapies. Finally, end-user segmentation across clinic, home care, and hospital settings underscores the growing importance of decentralized care models, where home infusion or self-administered prophylaxis requires robust training, monitoring, and safety net arrangements to preserve clinical outcomes and patient confidence.

How regional healthcare architectures, payer processes, and care delivery models drive differentiated adoption patterns across the Americas, EMEA, and Asia-Pacific

Geography continues to shape clinical practice patterns, regulatory pathways, reimbursement models, and adoption velocity across hereditary angioedema therapeutics. In the Americas, established specialty care networks, a strong private-sector payer presence, and concentrated centers of expertise often accelerate uptake of novel prophylactic agents and support robust specialty pharmacy integration. Clinical pathways in this region emphasize rapid on-demand access paired with growing home-based prophylaxis programs, reflecting both patient preference and system incentives to reduce acute care utilization.

In Europe, Middle East & Africa, heterogeneity in national health system structures, access criteria, and procurement mechanisms results in variable adoption timelines. Countries with centralized health technology assessment processes commonly require comprehensive evidence packages that demonstrate real-world effectiveness and cost implications, while other jurisdictions may prioritize managed access arrangements or named-patient programs to bridge access during evidence development. Across these markets, clinician networks and regional centers of excellence play a pivotal role in shaping guideline interpretation and treatment sequencing.

Asia-Pacific presents a diverse landscape where regulatory modernization, expanding specialty care capacity, and rising patient advocacy are accelerating interest in both on-demand and prophylactic options. In several markets, the growth of outpatient infusion centers, specialty pharmacy capabilities, and digital health platforms is enabling broader adoption of self-administration approaches. Across all regions, cross-border collaborations, multinational clinical registries, and real-world evidence platforms are increasing the comparability of outcomes and informing multinational market entry strategies and value demonstration efforts.

Examining how innovators and incumbents align clinical differentiation, distribution partnerships, and real-world evidence to secure durable commercial advantage

Company strategies in hereditary angioedema increasingly center on differentiated clinical profiles, delivery innovations, and evidence generation that supports payer and provider value propositions. Established biopharmaceutical companies with experience in biologics tend to leverage scale, integrated manufacturing, and existing commercial networks to introduce monoclonal antibodies and recombinant enzymes, while smaller biotechnology firms focus on highly targeted mechanisms, novel oral molecules, or formulation improvements that enable subcutaneous use and home administration. Strategic partnerships between platform innovators and specialty distributors are common, as they combine clinical differentiation with execution capabilities across complex supply chains.

Commercial playbooks emphasize curated patient journeys, including adherence support, nurse-led training for self-administration, and outcomes tracking that can validate therapeutic benefits in routine practice. Companies are also prioritizing lifecycle management initiatives-such as new formulations, label expansions, and pediatric data generation-to extend clinical utility and address underserved subpopulations. In competitive landscapes where multiple classes coexist, successful firms articulate clear comparative hypotheses and invest in head-to-head or pragmatic registries to substantiate real-world advantages. Finally, manufacturing resilience and supply chain transparency are treated as strategic differentiators, particularly for therapies requiring cold chain logistics or plasma-derived inputs.

Actionable tactics for aligning clinical evidence, decentralized delivery, supply chain resilience, and payer engagement to accelerate adoption and sustain access

Industry leaders should prioritize an integrated approach that aligns therapeutic differentiation with pragmatic delivery models and robust evidence generation. First, invest in longitudinal real-world studies and patient-reported outcome instruments to demonstrate not only clinical efficacy but also reductions in healthcare utilization and improvements in daily functioning. These data assets strengthen contracting conversations with payers and create a defensible narrative for preferential placement when clinical differences are nuanced. Second, optimize product formats and support services to enable decentralization of care-developing training modules, telehealth support, and home administration checklists will reduce barriers to adoption and improve adherence.

Third, proactively assess supply chain exposure to tariff shifts and consider regional manufacturing or inventory buffering for critical components to preserve continuity of care. Engaging early with logistics partners and integrating scenario planning into commercial launch timelines will mitigate disruption risk. Fourth, establish targeted payer engagement strategies that map value stories to specific distribution channels and end-user contexts; specialty pharmacies and hospital procurement teams require differentiated evidence and operational assurances to endorse new therapies. Finally, pursue collaborative research with centers of excellence and patient advocacy organizations to accelerate enrollment in registries and to refine outcome measures that matter most to patients and payers, reinforcing both clinical and commercial positioning.

A transparent mixed-methods evidence synthesis combining clinical literature, stakeholder interviews, registries, and trade analyses to support strategic decision-making

The research underpinning this analysis combined a structured review of peer-reviewed clinical literature, regulatory documents, and guidelines with expert interviews across clinical, payer, and commercial stakeholders. Data abstraction prioritized therapeutic mechanism, administration route, documented outcomes, safety signals, and patterns of care delivery. Real-world insights were synthesized from clinical registries and anonymized claims narratives to illuminate treatment pathways and site-of-care transitions without relying on proprietary market sizing datasets.

Qualitative inputs were validated through cross-stakeholder discussions to reconcile clinical practice variations and to surface emergent trends in patient preferences and distribution logistics. Supply chain and tariff-related analyses drew from customs regimes, trade policy announcements, and industry operational reports to characterize plausible impacts on manufacturing and distribution. Throughout the methodology, emphasis was placed on triangulating evidence sources, documenting assumptions, and highlighting areas where data gaps warrant targeted post-market studies or registries to inform long-term strategy.

Summarizing why integrated clinical innovation, supply chain resilience, and real-world evidence are essential to translate therapeutic advances into sustained patient access

The therapeutic landscape for hereditary angioedema is at an inflection point where mechanistic innovation, administration flexibility, and new evidence paradigms converge to create differentiated care pathways. Clinicians now have a broader armamentarium to tailor interventions to individual patient needs, balancing immediate on-demand interventions against longer-term prophylactic strategies that can improve quality of life. At the same time, commercial success increasingly depends on demonstrating value beyond controlled trials-through real-world effectiveness, reduced acute care dependency, and patient-centered outcomes.

Operational resilience is equally vital: manufacturers and distributors must manage supply chain complexity, adapt to policy shifts, and ensure that evolving formulations reach patients in clinic and home settings reliably. Stakeholders who integrate clinical, logistical, and economic perspectives into a unified strategy will be best positioned to translate therapeutic advances into sustainable patient benefit and commercial viability. Ongoing collaboration across clinicians, payers, advocacy groups, and manufacturers will be essential to refine guidelines, capture meaningful outcomes, and expand equitable access to innovative therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of gene therapy candidates aiming to provide durable control of hereditary angioedema attacks
  • 5.2. Expansion of real world evidence studies evaluating long term safety and efficacy of prophylactic therapies
  • 5.3. Increasing focus on patient centric outcome measures and quality of life in clinical trial design
  • 5.4. Integration of online treatment dispensing platforms to streamline home administration of HAE therapies
  • 5.5. Pricing pressure and evolving reimbursement policies impacting access to novel hereditary angioedema treatments
  • 5.6. Development of next generation monoclonal antibodies with extended half life for acute HAE episode prevention

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hereditary Angioedema Therapeutics Market, by Treatment Type

  • 8.1. On Demand
    • 8.1.1. Bradykinin Receptor Antagonist
    • 8.1.2. Kallikrein Inhibitor
    • 8.1.3. Plasma Derived C1 Inhibitor
    • 8.1.4. Recombinant C1 Inhibitor
  • 8.2. Prophylaxis
    • 8.2.1. Monoclonal Antibody
    • 8.2.2. Oral Small Molecule
    • 8.2.3. Plasma Derived C1 Inhibitor

9. Hereditary Angioedema Therapeutics Market, by Drug Class

  • 9.1. Bradykinin Receptor Antagonist
  • 9.2. Kallikrein Inhibitor
  • 9.3. Monoclonal Antibody
  • 9.4. Plasma Derived C1 Inhibitor
  • 9.5. Recombinant C1 Inhibitor

10. Hereditary Angioedema Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Hereditary Angioedema Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Specialty Pharmacies

12. Hereditary Angioedema Therapeutics Market, by End User

  • 12.1. Clinic
  • 12.2. Home Care
  • 12.3. Hospital

13. Hereditary Angioedema Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hereditary Angioedema Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hereditary Angioedema Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Takeda Pharmaceutical Company Limited
    • 16.3.2. CSL Behring AG
    • 16.3.3. BioCryst Pharmaceuticals, Inc.
    • 16.3.4. Pharming Group N.V.
    • 16.3.5. Ionis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLA